Phathom Pharmaceuticals, Inc.

8.66−2.37%1d

Data as of Aug 24, 2026 · end-of-day snapshot

AI summary

The PHAT read, in plain language

The AI summary distills PHAT's accumulation, technical and fundamental reads into a few plain-language sentences, generated fresh after you unlock.

In the full analysis:

Full narrative & key drivers
Technicals read
Fundamentals read
Accumulation read
Risks with evidence
Market context read

Short term · weeksMomentum negativeMid term · monthsDowntrendLong term · business qualityMixed

Mid term: price below key moving averages. Long term: fundamental metrics point in different directions.

Unlock PHAT: AI summary

CautionShort-term momentumRSI 40: negative lean. Mid-term trend: downtrend.
WatchVolume signalVolume signal tier C, alert level baseline.
WatchNext earningsEarnings scheduled for Oct 29, 2026, in 63 days.
WatchGrowth & qualityunlock to view
WatchValuationunlock to view
CautionTop risk flaggedunlock to view

The setup

Fundamental readings are mixed; mid-term technical readings show a downtrend (RSI 40). The mid-horizon read is currently softer than the long-horizon one. Short-term momentum is negative.

The full analysis breaks down the specific fundamental and risk factors behind this setup.

Volume signal tierC

Alert levelBaseline

Tier and alert level are a summary. Unlock PHAT to see the full accumulation read: relative-volume ratios, z-scores, money-flow and float turnover behind this signal.

−6.38%Return · 1w

−27.53%Return · 1m

−19.37%Return · 3m

−25.15%Return · 1y

−52.70%vs 52-week high

Price history PHAT · Daily View

Technicals

Technical readings

The latest end-of-day reading across momentum, trend and volatility signals, included free on every stock page.

DowntrendSee the full setup read: unlock PHAT

Automated read

Price is trading below its key moving averages: the mid-term picture reads as a downtrend. RSI is currently 40.

RSI (14)39.52Lower-neutral

MACD / signal-0.45 / -0.48Above signal line

SMA 5010.32Price below

SMA 20012.29Price below

EMA 209.31Price below

ADX (14)24.40Firming

+DI / −DI13.91 / 26.63−DI leading

ATR (14)0.485.6% of price — elevated daily swings

Stochastic %K29.32Mid-range

Bollinger bands (20)7.27 – 11.00Inside bands

ROC (10)1.05Positive over 10 sessions

Trend / momentum impulseBoth fallingTrend and momentum agree

Readings as of Aug 24, 2026 · end-of-day snapshot

Perspectives

How different investors read this

The same report, read from different investor horizons: what each would count for its case, and what each would count against it.

Long-term holder

Add or trim?

Short-term trader

Enter or wait?

Not yet invested

Start or skip?

Looking ahead

What has to go right?

Each horizon shown is argued both ways; unlocking shows the points behind both sides.

Evidence from this report, not a recommendation.

Unlock PHAT: the full evidence

Full analysis

What unlocking PHAT reveals

Short term · weeksMomentum negativeMid term · monthsDowntrendLong term · business qualityMixedMarket linkshows little relationship withthe S&P 500

These classifications are computed from PHAT's live data. The detail behind them is what unlocks.

Sample preview: figures are illustrative.

Company & theme write-up

Signal history

Signals & levels

AI narrative

Catalysts & risks

Fundamentals & valuation

Market context & correlations

Accumulation read

Sample preview: figures are illustrative.

Company & theme write-up

Signal history

AI narrative

Catalysts & risks

Accumulation read

Unlock PHAT: full analysis

Unlock

PHAT: full analysis

AI narrative · signals & history · social sentiment · full fundamentals

$9.90 USD

one-time · 30-day access

Unlocked in about 60 seconds
30-day access
No account needed

Analyzing a few names? Get 5 for $25.00 or 15 for $49.00: one-time, 30 days for the whole pack, swaps included.

Free weekly sample report

Get a full sample stock analysis in your inbox every week, no card, just the same read you see here on one hand-picked ticker.

Earnings

When does Phathom Pharmaceuticals, Inc. report earnings?

Phathom Pharmaceuticals, Inc. (PHAT) is scheduled to report earnings on Oct 29, 2026.

The date is confirmed rather than estimated, though companies do occasionally reschedule.

Data as of Aug 26, 2026

See who else reports soon

Need the raw data?Get PHAT + ~22,000 stocks as a clean CSV: every column, ready to load into a spreadsheet or notebook.

Build a dataset

Not investment advice. Everything on this page is descriptive market data and automated analysis provided for information only. It is not a recommendation, offer, or solicitation to buy or sell any security, and it does not account for your personal circumstances. Figures are from an end-of-day snapshot and may be delayed or restated; always verify against a primary source before acting. You are solely responsible for your own decisions.

About the signals.Buy and sell signals on this page are computed automatically from this stock’s own past price history: they summarise what happened after similar sessions, over the window each signal states. They are measurements of the past, not predictions, forecasts, or targets, and past behaviour does not determine future results. A signal is never a suggestion that you take any action.

$9.90one-time Unlock PHAT

The PHAT read, in plain language

Technical readings

How different investors read this

Long-term holder

Short-term trader

Not yet invested

Looking ahead

What unlocking PHAT reveals

Company & theme write-up

Signal history

Signals & levels

AI narrative

Catalysts & risks

Social sentiment

Fundamentals & valuation

Market context & correlations

Accumulation read

Company & theme write-up

Signal history

AI narrative

Catalysts & risks

Accumulation read

PHAT: full analysis

When does Phathom Pharmaceuticals, Inc. report earnings?

More Healthcare stocks

How different investors read this

Long-term holder

Short-term trader

Not yet invested

Looking ahead

The PHAT read, in plain language

Company & theme write-up

Signal history

Signals & levels

AI narrative

Catalysts & risks

Social sentiment

Fundamentals & valuation

Market context & correlations

Accumulation read